[1] Cheng C, Wentworth K, Shoback DM. New Frontiers in Osteoporosis Therapy. Annu Rev Med 2020;71:277-88.

[2] Bonnet N, Bourgoin L, Biver E, et al. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest 2019;129:3214-23.

[3] McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31.

[4] Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18: 4415-24.

[5] McDonald MM, Khoo WH, Ng PY, et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 2021;184:1940.

[6] Einhorn TA. Can an anti- fracture agent heal fractures? Clin Cases Miner Bone Metab 2010;7:11–14. 

[7] Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196–208. 

[8] Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27: 1229–41.

[9] Agarwala S, Vijayvargiya M. Repurposing denosumab for recalcitrant bone healing. BMJ Case Rep 2021;14:e238460.

[10] ElHawary H, Baradaran A, Abi-Rafeh J, et al. Bone healing and inflammation: principles of fracture and repair. Semin Plast Surg 2021; 35:198–203. 

[11] Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76–81. 

[12] Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep 2003;5:222–6.

[13] Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196–208. 

[14] HegdeV,JoJE, AndreopoulouP,etal. Effect of osteoporosis medications on fracture healing. Osteoporos Int 2016;27: 861–71.

[15] Cakir H, Van Vliet-Koppert ST, Van Lieshout EM, et al. Demographics and outcome of metatarsal fractures. Arch Orthop Trauma Surg 2011; 131:241–5.

[16] Tetsunaga T, Tetsunaga T, Nishida K, et al. Denosumab andalendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures. J Orthop Sci 2017;22:230–6.

[17] Phipps R, Mitlak Bruce H, Burr DB, et al. Pharmaceutical treatments of osteoporosis. Basic and Applied Bone Biology 2019 Jan 1;pp. 389–410. 

[18] Anastasilakis AD, Makras P, Yavropoulou MP, et al. Denosumab dis continuation and the rebound phenomenon: a narrative review. J Clin Med 2021;10:152.

[19] Di Bartolomeo M, Cavani F, Pellacani A, et al. Pulsed electro-mag netic field (PEMF) effect on bone healing in animal models: a review of its efficacy related to different type of damage. Biology (Basel) 2022;11:402.

[20] Cadossi R, Massari L, Racine-Avila J, et al. Pulsed electromagnetic field stimulation of bone healing and joint preservation: cellular mechanisms of skeletal response. J Am AcadOrthopSurgGlobResRev2020;4:e1900155. 

[21] Schlickewei CW, Kleinertz H, Thiesen DM, et al. Current and future concepts for the treatment of impaired fracture healing. Int J Mol Sci 2019;20:5805.

[22] Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open- label, parallel- group, phase 2 study. Lancet Oncol 2013;14:901–8. 

[23] Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant- cell tumor of bone. Clin Cancer Res 2012;18:4415–24.

[24] Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196–208. 

[25] Agarwala S, Vijayvargiya M. Repurposing denosumab to stabilize acetabular Protrusio: Obviating surgery. Open J Orthop 2020;10:110–5.